NEX-20A

Nanexa AB · Phase 1 active Small molecule

NEX-20A is a subcutaneous prolonged-release injection developed by Nanexa AB. Currently in early clinical development, it has completed a Phase 1 trial assessing safety, tolerability, and pharmacokinetics in healthy subjects.

At a glance

Generic name	NEX-20A
Sponsor	Nanexa AB
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

NEX-20A CI brief — competitive landscape report
NEX-20A updates RSS · CI watch RSS
Nanexa AB portfolio CI